HC Wainwright Lowers Agenus (NASDAQ:AGEN) Price Target to $7.00

Agenus (NASDAQ:AGEN) had its price objective lowered by equities research analysts at HC Wainwright from $8.00 to $7.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 131.02% from the company’s current price.

A number of other analysts also recently issued reports on the stock. William Blair downgraded shares of Agenus from an “outperform” rating to a “market perform” rating in a report on Thursday, July 18th. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. B. Riley decreased their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Baird R W cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $7.00 price objective (up from $3.00) on shares of Agenus in a report on Friday, July 19th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $10.00.

Agenus Trading Down 2.4 %

Shares of AGEN stock opened at $3.03 on Tuesday. Agenus has a twelve month low of $2.98 and a twelve month high of $19.69. The stock has a market cap of $65.36 million, a price-to-earnings ratio of -0.27 and a beta of 1.39. The company’s 50-day moving average price is $4.79 and its 200-day moving average price is $8.81.

Institutional Trading of Agenus

Several hedge funds have recently modified their holdings of AGEN. Point72 DIFC Ltd acquired a new position in shares of Agenus during the second quarter worth about $51,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Agenus during the 2nd quarter worth $106,000. Exchange Traded Concepts LLC grew its stake in shares of Agenus by 52.0% during the third quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock worth $151,000 after purchasing an additional 9,422 shares in the last quarter. Blair William & Co. IL acquired a new position in shares of Agenus during the second quarter worth $441,000. Finally, FMR LLC increased its holdings in Agenus by 47.1% in the third quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock valued at $467,000 after buying an additional 27,309 shares during the last quarter. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.